Inherited Retinal Disease

Gene therapy for choroideremia shows promising results in Phase 2 study

Timrepigene emparvovec, a gene therapy for choroideremia, has demonstrated safety and efficacy in maintaining visual acuity when administered bilaterally, according to a study. The therapy was well tolerated with mostly mild to moderate side effects, and no significant increase in serious adverse events was observed with sequential eye treatments. The...